Manfred, there will be at best 10% of pediatricians buying the Colormate.
Home Health Care will not buy the Colormate.
Hospital Newborn units will buy the Colormate, count 20% to 30 % year per year growth.
The disposables costs will limit the use of the Colormate.
If we use 14,000,000 shares in my business model then the earnings per share will be even lower, and next year stock price based on the Colormate sales will be $4 to $8.
About 50% of babies will have jaundice.
But, only 10% of babies are tested for bilirubin, these are mainly the ones with Blood group incompatibility between mother and baby types.
Cephalocaudal progression of jaundice and its relation to the actual blood bilirubin level? Any pediatrician could use their eyes to decide if they want to test or not, jaundice above your chest rarely get test, jaundice progression below the chest do get test. Race does not impaired this ability significantly.
The number of tests will be higher than the 10% of babies usually tested for, because the ease of use will make it easier to do it.
But, even babies in phototherapy are now tested less than before, once or twice a day for most cases, ease of use will increase testing maybe to one time more, it does costs more to test the extra one (the limiting factor is extra costs).
There is very, very little use for the Colormate beyond one week of life.
Ask a general practitioner or family practice physician about the use of the Colormate in adults and you will have your answer about the need for it. Close to zero.
The other technologies are probably the future, but CCSI should try the glucose market (like SPRX wisely is doing).
Thank you for your patience,
Respecfully,
cacaito
|
